Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
IPO Year: 2019
Exchange: NYSE
Website: avantorsciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/28/2024 | $30.00 | Overweight | Wells Fargo |
| 7/10/2024 | $30.00 → $23.00 | Buy → Neutral | Citigroup |
| 1/4/2024 | $19.50 → $26.00 | In-line → Outperform | Evercore ISI |
| 12/11/2023 | $21.00 → $28.00 | Market Perform → Outperform | TD Cowen |
| 9/28/2023 | $22.00 | Mkt Perform | Bernstein |
| 7/31/2023 | $22.00 → $21.00 | Outperform → In-line | Evercore ISI |
| 7/31/2023 | Outperform → Mkt Perform | William Blair | |
| 6/21/2023 | $27.00 | Outperform | RBC Capital Mkts |
| 12/14/2022 | $24.00 | Hold | Deutsche Bank |
| 10/5/2022 | $28.00 | Neutral → Buy | Citigroup |
4 - Avantor, Inc. (0001722482) (Issuer)
3 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7%Net income of $57.8 million; Adjusted EBITDA of $302.5 millionDiluted GAAP EPS of $0.08; adjusted EPS of $0.26Operating cash flow of $244.8 million; free cash flow of $204.0 millionRADNOR, Pa., Oct. 25, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its third fiscal quarter ended September 30, 2024. "Our team delivered another quarter o
RADNOR, Pa., Sept. 27, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, will release its third quarter 2024 financial results before the market opens on Friday, October 25, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days. About AvantorAvantor® is a leading life science tools company and global provider of mission
Accelerates ongoing business transformation and sharpens Avantor's strategic focus Strengthens balance sheet with proceeds to be used for debt paydownRADNOR, Pa., Aug. 16, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the signing of a definitive agreement to divest its clinical services business, including kitting, biorepository, and related equipment and ancillaries (collectively "Clinical Services"), to Audax Private Equity ("Audax") for a transaction value of approximately $650 million. "Today's announcement is an important step fo
Net sales of $1.70 billion, decrease of 2.4%; organic decline of 2.0%Net income of $93 million; Adjusted EBITDA of $306 millionDiluted GAAP EPS of $0.14; adjusted EPS of $0.25Operating cash flow of $281 million; free cash flow of $235 millionRADNOR, Pa., July 26, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2024."Our teams delivered another solid quarter with sequential improvements to all key financial metrics. Improved mix from increased bioprocessing revenue together with t
RADNOR, Pa., June 28, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2024 financial results before the market opens on Friday, July 26, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days. About AvantorAvantor® is a leading life science tools company and global prov
Net sales of $1.68 billion, decrease of 5.6%; organic decline of 6.3%Net income of $60 million; Adjusted EBITDA of $283 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.22Operating cash flow of $142 million; free cash flow of $107 millionRADNOR, Pa., April 26, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal quarter ended March 31, 2024. "The year is off to a good start as first quarte
RADNOR, Pa., April 1, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2024 financial results before the market opens on Friday, April 26, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the
Fourth Quarter 2023 Net sales of $1.72 billion, decrease of 4.0%; core organic decline of 4.8%Net income of $98.5 million; Adjusted EBITDA of $302.1 millionDiluted GAAP EPS of $0.15; adjusted EPS of $0.25Operating cash flow of $251.6 million; free cash flow of $201.0 millionFull Year 2023 Net sales of $6.97 billion, decrease of 7.3%; core organic decline of 5.2%Net income of $321.1 million; Adjusted EBITDA of $1,309.1 millionDiluted GAAP EPS of $0.47; adjusted EPS of $1.06Operating cash flow of $870.0 million; free cash flow of $723.6 millionAdjusted net leverage of 3.9X; repaid approximately $850 million of debt in 2023RADNOR, Pa., Feb. 14, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a
RADNOR, Pa., Jan. 24, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February, 14, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avanto
RADNOR, Pa., Sept. 29, 2023 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and technology industries, will release its third quarter 2023 financial results before the market opens on Friday, October 27, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the earnings call, visit Events & Presentations on the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be av
RADNOR, Pa., Nov. 20, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that President and CEO, Michael Stubblefield, will be participating in a fireside chat at the Evercore ISI HealthCONx Conference in Coral Gables, Florida on Tuesday, December 3, at 9:10 a.m. Eastern Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days. About AvantorAvantor® is a leading life science tools company and gl
Agreement Expands Access to Pioneering Proteomics Technology Across the U.S. and Canadian Markets Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, has announced a distribution agreement with Avantor® (NYSE:AVTR), a global leader in mission-critical products and services for the life sciences and advanced technology industries. Through this collaboration, Avantor will distribute Quantum-Si's Next-Generation Protein Sequencing (NGPS) portfolio, providing researchers across all market segments in the U.S. and Canada streamlined access to these innovative proteomics solutions. The distribution agreement enables Avantor to offer Qu
RADNOR, Pa., Nov. 14, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the opening of its new flagship Bridgewater Innovation Center. The state-of-the-art research and development facility, located in Bridgewater, NJ, is part of Avantor's network of 13 research and innovation centers across the globe. Avantor's new Bridgewater Innovation Center spans 60,000 square feet, doubling its previous laboratory and pilot plant capacity
RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat. Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transform
Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7%Net income of $57.8 million; Adjusted EBITDA of $302.5 millionDiluted GAAP EPS of $0.08; adjusted EPS of $0.26Operating cash flow of $244.8 million; free cash flow of $204.0 millionRADNOR, Pa., Oct. 25, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its third fiscal quarter ended September 30, 2024. "Our team delivered another quarter o
Avantor and NIBRT have formed a new partnership to supply advanced Masterflex® equipment, essential products, and expert training to foster innovations in biopharma manufacturingRADNOR, Pa., Oct. 23, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced an expanded partnership with the National Institute for Bioprocessing Research and Training (NIBRT). The new collaboration will focus on addressing urgent bottlenecks in biopharma manufacturing, particularly in downstream optimization for monoclonal antibodies (mAbs), by providing cutting-edge eq
Audax Private Equity ("Audax") has completed its acquisition of the clinical services business of Avantor, Inc. (NYSE:AVTR) and, in close collaboration with the employees, has re-branded the business as Resonant Clinical Solutions ("Resonant" or "the Company"). Resonant is comprised of three well-respected brands – EPL Archives, MESM, and Therapak. These long-standing brands, whose roots and lineage extend as far back as the 1970s, provide a comprehensive, quality-focused service offering to its pharmaceutical, biotechnology, contract research organization (CRO), and diagnostic laboratory customers. Beyond investing in the business and operations of Resonant, Audax will look to drive organ
RADNOR, Pa., Oct. 18, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it has closed the divestiture of its clinical services business to Audax Private Equity in a transaction valued at approximately $650 million. Avantor expects the transaction to result in approximately $500 million in after-tax cash proceeds and a reduction of approximately $50 million in capitalized leases. After-tax proceeds will be used to paydown debt. "This transaction not only strengthens our balance sheet and reduces interest expense, but also enables us to sharpen
Recognition highlights commitment to Avantor Business System (ABS) principles to enhance customer experience RADNOR, Pa., Sept. 30, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, announced today that the Company's NuSil brand has received the 2024 North American Daily Kaizen Management award from the Kaizen Institute. NuSil, the leading global provider of high-purity silicones materials engineered to serve the needs of healthcare and advanced technologies manufacturers, was recognized for their commitment to operational excellence and relentless focus o
RADNOR, Pa., Sept. 27, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, will release its third quarter 2024 financial results before the market opens on Friday, October 25, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days. About AvantorAvantor® is a leading life science tools company and global provider of mission
8-K - Avantor, Inc. (0001722482) (Filer)
10-Q - Avantor, Inc. (0001722482) (Filer)
8-K - Avantor, Inc. (0001722482) (Filer)
144 - Avantor, Inc. (0001722482) (Subject)
144 - Avantor, Inc. (0001722482) (Subject)
10-Q - Avantor, Inc. (0001722482) (Filer)
8-K - Avantor, Inc. (0001722482) (Filer)
8-K - Avantor, Inc. (0001722482) (Filer)
8-K - Avantor, Inc. (0001722482) (Filer)
SD - Avantor, Inc. (0001722482) (Filer)
Wells Fargo initiated coverage of Avantor with a rating of Overweight and set a new price target of $30.00
Citigroup downgraded Avantor from Buy to Neutral and set a new price target of $23.00 from $30.00 previously
Evercore ISI upgraded Avantor from In-line to Outperform and set a new price target of $26.00 from $19.50 previously
TD Cowen upgraded Avantor from Market Perform to Outperform and set a new price target of $28.00 from $21.00 previously
Bernstein initiated coverage of Avantor with a rating of Mkt Perform and set a new price target of $22.00
Evercore ISI downgraded Avantor from Outperform to In-line and set a new price target of $21.00 from $22.00 previously
William Blair downgraded Avantor from Outperform to Mkt Perform
RBC Capital Mkts initiated coverage of Avantor with a rating of Outperform and set a new price target of $27.00
Deutsche Bank initiated coverage of Avantor with a rating of Hold and set a new price target of $24.00
Citigroup upgraded Avantor from Neutral to Buy and set a new price target of $28.00
RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat. Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transform
Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees
NEW YORK, July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions.Schneider National Inc. (NYSE:SNDR) will replace U.S. Silica Holdings Inc. (NYSE:SLCA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 31. Apollo Global Management Inc. (NYS
RADNOR, Pa. , June 21, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced that Corey Walker has rejoined the company as President of Avantor's Laboratory Solutions business, reporting to CEO Michael Stubblefield. "Corey's deep knowledge of our end markets and industry, coupled with his familiarity with our organization and customers, makes him the ideal leader for our Laboratory Solutions business," said Michael Stubblefield,
U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday. Shares of AT&T Inc. (NYSE:T) rose during Wednesday's session following second-quarter earnings. AT&T reported fiscal second-quarter 2024 operating revenues of $29.8 billion, down 0.4% year over year and missing the analyst consensus estimate of $29.9 billion. Adjusted EPS of 57 cents is in line with the analyst consensus estimate, according to data from Benzinga Pro. AT&T shares gained 3.1% to $18.78 on Wednesday. Here are some other big stocks recording gains in today’s session. PROG Holdings, Inc. (NYSE:PRG) shares jumped 20.4% to $41.71 after the company reported better-than-expected s
RBC Capital analyst Conor McNamara maintains Avantor (NYSE:AVTR) with a Outperform and raises the price target from $30 to $31.
Citigroup analyst Patrick Donnelly downgrades Avantor (NYSE:AVTR) from Buy to Neutral and lowers the price target from $30 to $23.
Evercore ISI Group analyst Vijay Kumar maintains Avantor (NYSE:AVTR) with a Outperform and lowers the price target from $28 to $27.
Across the recent three months, 5 analysts have shared their insights on Avantor (NYSE:AVTR), expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 2 1 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $26.8, a high estimate of $30.00, and a low estimate of $25.00. Observing a 2.29% increase, the current average has r
Barclays analyst Luke Sergott maintains Avantor (NYSE:AVTR) with a Overweight and lowers the price target from $28 to $25.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Below are some instances of options activity happening in the Health Care sector: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume FULC PUT TRADE BULLISH 06/21/24 $7.00 $141.2K 50 1.4K GTHX PUT SWEEP BEARISH 07/19/24
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)